Shots:

• The P-III ARAMIS study involves assessing of Nubeqa (600mg- bid) + ADT vs PBO + ADT in 1-509 patients in a ratio (2:1) with nmCRPC who were receiving a concomitant GnRH analog or had a bilateral orchiectomy
• The P-III ARAMIS study resulted in meeting its 1EPs i.e- improvement in MFS (40.4 vs 18.4mos.)
• Nubeqa is an androgen receptor inhibitor (ARi) binding it with high affinity- thus inhibiting the growth of prostate cancer cells and is an approved therapy in the US- Brazil and Japan. Bayer has filed for its approval in the EU

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Bayer